Actinogen Medical Limited
ACW
Rank in Stocks
#18493
Actinogen Medical Limited is an Australian biotechnology company dedicated to... Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11Γ-HSD1 enzyme, is currently in Phase 2 clinical trials. This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome. Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.
Share Price
$0.03391731
Last synced: 2026-11-10
Market Cap
$131.40M
Change (1 day)
-2.00%
Change (1 year)
5.93%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Actinogen Medical Limited (ACW)
Category
Healthcare
EPS for Actinogen Medical Limited (ACW)
EPS as of June 2026 TTM: $0.00
According to Actinogen Medical Limited's latest financial reports, its current EPS (TTM) is $0.00. At the end of 2025 the company had an EPS of 0.00, equal to its 2024 EPS of 0.00.
EPS history for Actinogen Medical Limited from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -20.00% |
| 2025 | 0.00 | -20.00% |
| 2024 | 0.00 | 5.26% |
| 2023 | 0.00 | 2.70% |
| 2022 | 0.00 | 85.00% |
| 2021 | 0.00 | -35.48% |
| 2020 | 0.00 | -50.79% |
| 2019 | $-0.01 | 3.28% |
| 2018 | $-0.01 | 60.53% |
| 2017 | 0.00 | -9.52% |
| 2016 | 0.00 | -55.79% |
| 2015 | $-0.01 | 251.85% |
| 2014 | 0.00 | -20.59% |
| 2013 | 0.00 | -92.00% |
| 2012 | $-0.04 | 21.43% |
| 2011 | $-0.04 | 32.08% |
| 2010 | $-0.03 | -16.67% |
| 2009 | $-0.03 | 70.05% |
| 2008 | $-0.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -460,688.24% |
US
|
|
| $-7.07 | 207,841.18% |
US
|
|
| $-5.29 | 155,488.24% |
AU
|
|
| $12.88 | -378,926.47% |
BE
|
|
| $21.56 | -634,217.65% |
NL
|
Questions about Actinogen Medical Limited's earnings per share (EPS)
What is Actinogen Medical Limited's earnings per share (EPS)?
Actinogen Medical Limited's earnings per share (EPS) over the last twelve months is $0.00, as of Jun 2026.
What was Actinogen Medical Limited's earnings per share (EPS) in 2025?
In 2025, Actinogen Medical Limited's earnings per share (EPS) was 0.00, compared with 0.00 in 2024.
How has Actinogen Medical Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Actinogen Medical Limited's earnings per share (EPS) was highest in 2025 (0.00) and lowest in 2025 (0.00).
How does Actinogen Medical Limited's earnings per share (EPS) compare with similar companies?
Actinogen Medical Limited's earnings per share (EPS) ($0.00) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.